EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice - Wikidata - wikimedia - TriplyDB

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

http://www.wikidata.org/entity/Q30664830

about

Predictive biomarkers in precision medicine and drug development against lung cancer Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options Epidermal growth factor receptor in non-small cell lung cancer Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.Identification of lung adenocarcinoma mutation status based on histologic subtype: Retrospective analysis of 269 patients Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report Harnessing plasma genotyping for precision therapy against lung cancer.Role of epidermal growth factor receptor in lung cancer and targeted therapies.Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians.Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma.Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland.Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.Emerging resistance pathways in lung cancer: what has ROS-1 taught us?

P2860

Q26824536-D838CE7A-3F75-41B8-B125-F0B9FC509185 Q28075291-A34A19BF-9465-4056-B9EC-B3E46616E9B8 Q28088636-740F8A14-8EDF-43F2-BE06-B64938E884F7 Q33733770-F88C5485-30A8-4551-8CEF-C3280AE83B05 Q33798605-D05FACD8-2812-4EA3-8738-1F01276C6325 Q34216253-FBA92D55-84FB-4FA7-985B-A9115A51E9FD Q34497467-BEEBFBEA-6780-4C5A-A07C-C1498A2178BD Q34781380-C2D9A7E2-FDDD-4E78-81DF-08F74D1ACA8D Q34809526-B1F54C93-B478-4136-9671-AC3AA09B2827 Q35125795-5D82F44F-AAA0-4AF1-BB8A-7C718BAEE4DB Q35257336-90422203-3A78-48C2-AE11-AB21DDC43693 Q35478632-1C36FB7D-96C2-40B1-BAC0-E06EE8F691FD Q35958288-404A2014-A67B-49D8-A8D8-5717FB7D3F0F Q36228469-5F461B9F-D639-4F42-9BD0-27C1F803B081 Q36250691-33A89EEC-B0F7-4949-9F82-D663925C7CAA Q36417758-BF1B0512-98BB-4866-9831-5D3F55E72BB9 Q36477758-7E1F904C-0FF5-465E-9E03-A47C3FFC0038 Q36640486-F3B8F7DC-A3EA-415C-BEA8-0D767F8B95B0 Q36838905-CE838F6F-F590-42E8-BC08-F64E11CC6031 Q37411128-A56037BD-86A4-47D4-A374-07EC1EEFFD64 Q37679981-03A0DF30-CD12-4E0A-A778-8421C17A44D1 Q38335360-3978FAD4-D60E-4205-BADD-E49995861EC0 Q38661269-263A9EA5-1D43-4BCF-8BBC-9AC008CE4237 Q38676692-EC8A04E6-DA7F-4504-86DA-221501036A08 Q39129178-834F3E5B-C141-4C6E-BFC0-DC3A1ADEBD72 Q40829674-FB642F8C-C17D-48E8-8B37-8B55E70513B7 Q41437605-A5F9A9D6-FF89-40CF-B6DD-3DA296C90BDB Q41612456-310723A4-0F44-4226-B024-DB82390223D2 Q47104483-A80E37B9-FAF1-4E9E-800B-2280A089DB0C Q47143835-DA2D9909-B3A7-4397-84B2-37AAA585BF96 Q54962187-30CB3339-3561-4097-BCD6-CF5BB6D4FC46 Q55258220-E2F3F3DC-5399-4DD6-88B0-D9DF345E153B

P2860

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

http://www.wikidata.org/entity/Q30664830

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

EGFR mutational status in a la ...... ents: data from daily practice

@ast

EGFR mutational status in a la ...... ents: data from daily practice

@en

type

label

EGFR mutational status in a la ...... ents: data from daily practice

@ast

EGFR mutational status in a la ...... ents: data from daily practice

@en

prefLabel

EGFR mutational status in a la ...... ents: data from daily practice

@ast

EGFR mutational status in a la ...... ents: data from daily practice

@en

P1433

Q30664830-05FFE01C-1317-4E24-A319-398E8F49BBA9

P1476

Q30664830-7C22B9CF-02BA-45C5-8C02-201AF38C180C

P2093

Q30664830-0B9D283A-08DA-415E-8725-FCB8621763CD

Q30664830-2A9DA0CF-8172-419D-B717-DCE63CCFDD5A

Q30664830-341DB6B8-02FE-4BEA-B397-D92EC9A4278B

Q30664830-5A5E3774-2D97-4A8A-AB30-1CAB748530E3

Q30664830-6C91FC98-16FD-4E3F-BB70-6363D9ACD989

Q30664830-6E56DBA9-9AF1-4582-84E3-1C10D0892E91

Q30664830-797861DB-EB88-41BA-BC14-A18D09AC0539

Q30664830-883AD8A7-450F-432A-B34D-126948829A13

Q30664830-9B4D7CBE-9CDA-4BB4-AD7F-A92AA52D3027

Q30664830-9E3E2F27-5041-4CEB-9C10-84DD8624CABC

P2860

Q30664830-0211459C-54CF-463D-843D-0EFFFE110F74

Q30664830-0C3D8786-4BC2-4EB2-9369-38A60EAD06E8

Q30664830-0FF076C8-2A96-49BF-8ED1-1661EBC1CBFD

Q30664830-12DA3717-7A3B-49C7-8827-6F475C983F47

Q30664830-16226A6A-574C-48F2-B0CF-57C9DDF07CF7

Q30664830-1854FC8F-BF3F-4769-BCC4-ACCA536213DB

Q30664830-1CDA77D8-8E30-41EF-841A-250023267F42

Q30664830-20F4061D-8193-481B-ACBC-B65B8B6C08A3

Q30664830-217ADE77-F12E-4BCD-A9A5-DF53389A4F82

Q30664830-22907078-1A7C-4BBA-9BFF-97E1049638F0

P2888

Q30664830-4DFFFD44-FFFE-4919-B760-79BD28B79648

P304

Q30664830-D5597CBD-CC43-42E3-ADCA-7B54BEA7537D

P31

Q30664830-513FC2F9-3C5F-4BEB-AC45-200788540678

P356

Q30664830-2CEE5613-D184-422C-A9E2-26FBDB282ECB

P407

Q30664830-F6D1B57F-880F-4A2A-995B-18222BD0C384

P433

Q30664830-301958A2-7097-4C47-844E-9A71EB6ABAB3

P478

Q30664830-D1A58571-ED47-4DFD-AC3B-AAF6DC6C8BF5

P50

Q30664830-61808C0F-4677-406D-8FD6-D44C2571E1E7

Q30664830-A867D986-9053-4D26-918B-3447649ABACE

P577

Q30664830-513428BF-D21D-4524-9E9B-A03668EBF8B0

P5875

Q30664830-F93C4D64-6AFB-48EC-AF0E-0DBDE44305A9

P6179

Q30664830-13515DF7-B27C-435E-8579-615912EEFDA3

P698

Q30664830-A997B37D-A91F-4594-A0FB-B015EB29B2DD

P932

Q30664830-13D0C828-5AAD-4F88-AC55-C35C759BF320

P356

P1433

British Journal of Cancer

P1476

EGFR mutational status in a la ...... ents: data from daily practice

@en

P2093

A Gschwendtner

http://www.w3.org/2001/XMLSchema#string

A Hartmann

http://www.w3.org/2001/XMLSchema#string

C Schulz

http://www.w3.org/2001/XMLSchema#string

E Geissinger

http://www.w3.org/2001/XMLSchema#string

F S Fuchs

http://www.w3.org/2001/XMLSchema#string

P Ruemmele

http://www.w3.org/2001/XMLSchema#string

R J Rieker

http://www.w3.org/2001/XMLSchema#string

R Stoehr

http://www.w3.org/2001/XMLSchema#string

S Gahr

http://www.w3.org/2001/XMLSchema#string

S Gattenloehner

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1

KRAS mutations in non-small cell lung cancer

A sequencing method based on real-time pyrophosphate

Real-time DNA sequencing using detection of pyrophosphate release

P2888

P304

1821-1828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.511

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang M Brueckl

Joachim Hans Ficker

P577

2013-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256425352

http://www.w3.org/2001/XMLSchema#string

P6179

1023449966

http://www.w3.org/2001/XMLSchema#string

P698

24002608

http://www.w3.org/2001/XMLSchema#string

P932

3790166

http://www.w3.org/2001/XMLSchema#string